Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Biological: 2mg INO-5150 and electroporation device CELLECTRA®-5P; Device: Electroporation using CELLECTRA®-5P; Biological: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P; Biological: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P; Biological: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

Detailed Description

Phase I, open label study of INO-5150 (DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA)) alone or co-administered with INO-9012 (IL-12 plasmid) delivered intramuscularly followed by EP using the CELLECTRA®-5P device in adult males with biochemically relapsed prostate cancer following definitive local therapy (e.g. prostatectomy, external beam radiation, or brachytherapy). Four injections will be administered to approximately 60 eligible subjects who consent to participate in the study. Subjects will be monitored for safety and immunogenicity through Week 72.

• Study Type: Interventional
• Enrollment (Actual): 62
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21204
      • Chesapeake Urology Research Associates
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Karmanos Cancer Institute
  • Nebraska
    • Omaha, Nebraska, United States, 68130
      • GU Research Network, LLC/ Urology Cancer Center
  • New York
    • New York, New York, United States, 10065
      • Weill Cornell Medical College
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina Lineberger Cancer Center
  • Ohio
    • Cleveland, Ohio, United States, 44915
      • Cleveland Clinic
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Sidney Kimmel Cancer Center - Thomas Jefferson University
    • Pittsburgh, Pennsylvania, United States, 15232
      • UPMC
  • South Carolina
    • Myrtle Beach, South Carolina, United States, 29572
      • Carolina Urologic Research Center
  • Washington
    • Seattle, Washington, United States, 98109
      • Seattle Cancer Care Alliance

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Men aged 18 to 90 years with a histologic diagnosis of prostate cancer;

2. c. Biochemical recurrence following local therapy, either surgery or radiation. Rising PSA defined as:

   • After definitive surgery, e.g.

     • After radical prostatectomy, two PSA measurements of ≥ 1.0 ng/mL at least one week apart;
     • After cryosurgery, two PSA measurements of ≥ 2.0 ng/mL at least one week apart;
     • Other definitive surgical procedures may be permissible upon the approval of the medical monitor OR
   • After radiation therapy (e.g., external beam radiation, brachytherapy, or salvage/adjuvant radiation therapy after surgery), two post radiation PSA measurements level of nadir plus 2.0 ng/mL at least one week apart.;

3. Serum testosterone level:

   i) Subjects with no history of androgen deprivation therapy:

   • A single measurement greater than 150 ng/dL or 5.2 nmol/L within 3 months of enrollment

   ii) Subjects with a history of androgen deprivation therapy (either in adjuvant or biochemical relapse setting):

   • The two most recent measurements of serum testosterone prior to enrollment must fulfill the following criteria:

     • Both measurements are greater than 150 ng/dL or 5.2 nmol/L;
     • The two measurements are spaced at least 14 days apart;
     • Both must be measured within 3 months of enrollment;
4. Normal electro cardio gram (ECG) or ECG with no clinically significant findings;

5. Adequate bone marrow, hepatic, and renal function tests within 30 days prior to enrollment:

   • CBC (except platelets and hemoglobin), serum chemistry, liver panel, and CPK values ≤ Grade 1 abnormality as defined in CTCAE v 4.03 dated June 14, 2010
   • Platelets ≥ 75,000 /mL;
   • Hemoglobin ≥ 9.0 g/dL;
6. No desire or plans to father new children during the study and/or have a prior vasectomy

Exclusion Criteria:

1. PSA doubling time (PSA-DT) of ≤ 3 months, using 2 PSA values at least 4 weeks apart, calculated according to the Memorial Sloan-Kettering Cancer Center nomogram (https://www.mskcc.org/nomograms/prostate/psa-doubling-time);
2. Clinical or radiologic evidence of distant metastatic disease other than small volume (<1.5 cm) nodes, this should be tested within 12 months from enrollment;
3. Receipt of investigational therapy in a clinical trial setting within 30 days of enrollment;
4. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
5. Prior major surgery or radiation therapy within 4 weeks of enrollment;
6. Any prior chemotherapy, except short-course neo-adjuvant or adjuvant chemotherapy that had been stopped for at least 6 weeks prior to Study enrollment;
7. Active AIDS / HIV infection, clinically uncontrolled immune deficiency disorders;
8. Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents;
9. Recipient of any blood product and immunotherapy (such as anti-PD1, anti-PDL-1 and anti-CTLA4) within 3 months of enrollment;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A; 2mg INO-5150 and electroporation device CELLECTRA®-5P	Biological: 2mg INO-5150 and electroporation device CELLECTRA®-5P; 2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P; Device: Electroporation using CELLECTRA®-5P; Electroporation device CELLECTRA®-5P
Experimental: Arm B; 8.5mg INO-5150 and electroporation device CELLECTRA®-5P	Device: Electroporation using CELLECTRA®-5P; Electroporation device CELLECTRA®-5P; Biological: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P; 8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
Experimental: Arm C; 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P	Device: Electroporation using CELLECTRA®-5P; Electroporation device CELLECTRA®-5P; Biological: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P; 2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
Experimental: Arm D; 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P	Device: Electroporation using CELLECTRA®-5P; Electroporation device CELLECTRA®-5P; Biological: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P; 8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability of INO-5150 alone or with INO-9012 delivered via IM EP ( Incidence of adverse events, Injection site reactions, Changes in safety laboratory parameters)	Incidence of adverse events (all, severe, [NCI CTCAE v4.03] and serious) classified by system organ class (SOC), preferred term, severity, and relationship to study medication and schedule; Injection site reactions; Changes in safety laboratory parameters .	72 weeks
Antigen specific immune response of INO-5150 alone or with INO-9012 delivered via IM EP	Antigen specific cellular immune responses	72 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PSA response rate by PSA testing	PSA response	72 weeks

Collaborators and Investigators

• Sponsor: Inovio Pharmaceuticals
• Investigators: Study Director: Ildi Csiki, MD, PH.D., Inovio Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: July 1, 2015
• Primary Completion (Actual): December 12, 2017
• Study Completion (Actual): December 12, 2017

Study Registration Dates

• First Submitted: July 29, 2015
• First Submitted That Met QC Criteria: July 31, 2015
• First Posted (Estimate): August 3, 2015

Study Record Updates

• Last Update Posted (Actual): December 26, 2017
• Last Update Submitted That Met QC Criteria: December 21, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Keywords: PSA
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms
• Other Study ID Numbers: PCa-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: combined results when available will be made available